**Conflict of interest**

The authors do not have any conflict of interest.

*New Developments in Behavioral Pharmacology DOI: http://dx.doi.org/10.5772/intechopen.93700*

*Behavioral Pharmacology - From Basic to Clinical Research*

effect of chrysin.

**7. Conclusion**

health.

**Conflict of interest**

The authors do not have any conflict of interest.

rout of the aqueous crude extract of *Montanoa tomentosa*, a Mexican plant traditionally recommended for the treatment of anxiety and other illness of women, reduces anxiety-like behavior in the elevated plus maze [101]. Said actions have been related with pharmacological actions on the GABAA receptors [102]. Additionally, secondary metabolites from plants, for example, the flavonoids are reported with anxiolytic properties in behavioral models in rats. In this way, 2 and 4 mg/kg, i.p., of the flavonoid chrysin produces anxiolytic-like effects in rats with surgical menopause subjected to the elevated plus maze and the light/dark test [103]; the said effects were produced through action on the GABAA receptor because the pretreatment with 1 mg/kg picrotoxin, a noncompetitive antagonist of the GABAA receptor, cancels the anxiolytic-like

As mentioned before, behavioral pharmacology is an interdisciplinary field. The present chapter tried to reflect briefly the essence of behavioral pharmacology through an anecdotical review of its developments in areas familiar to the authors. All findings mentioned above underline the importance of the research in behavioral pharmacology on the understanding of the neurobiology of different disorders and the mechanism of action of drugs used to treat such disorders, and at the same time, provide a perspective on the current research done in this growing area, which is and will be a cornerstone in the understanding of human behavior and mental

**16**
